keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC50 values of 4, 4, and 6 µM, respectively. It also affects non-cancerous cells, including NIH3T3 mouse fibroblasts and OL human foreskin fibroblasts, with LC50s of 7 and 5 µM, respectively. Furthermore, at a concentration of 100 µM, L-K6L9 induces hemolysis in isolated human erythrocytes.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | お問い合わせ | ¥ 22,500 |
5 mg | お問い合わせ | ¥ 88,500 |
10 mg | お問い合わせ | ¥ 155,500 |
25 mg | お問い合わせ | ¥ 330,500 |
説明 | L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC50 values of 4, 4, and 6 µM, respectively. It also affects non-cancerous cells, including NIH3T3 mouse fibroblasts and OL human foreskin fibroblasts, with LC50s of 7 and 5 µM, respectively. Furthermore, at a concentration of 100 µM, L-K6L9 induces hemolysis in isolated human erythrocytes. |
分子量 | 1804.48 |
分子式 | C90H174N22O15.XCF3COOH |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
L-K6L9 TFA Inhibitor inhibitor inhibit